V116
Biological
Merck Sharp & Dohme Corporation
Total Payments
$683,700
Transactions
217
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $658,656 | 197 | 0 |
| 2019 | $25,044 | 20 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $683,700 | 217 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults | Merck Sharp & Dohme Corporation | $658,656 | 0 |
| A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety,Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine inAdults | Merck Sharp & Dohme Corporation | $25,044 | 0 |
Top Doctors Receiving Payments for V116
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Mesa, AZ | $683,700 | 217 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $683,700
Product Information
- Type Biological
- Total Payments $683,700
- Total Doctors 0
- Transactions 217
About V116
V116 is a biological associated with $683,700 in payments to 0 healthcare providers, recorded across 217 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2019 to 2020. In 2020, $658,656 was paid across 197 transactions to 0 doctors.
The most common payment nature for V116 is "Unspecified" ($683,700, 100.0% of total).
V116 is associated with 2 research studies, including "A Phase 1,Phase 2, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine in Adults" ($658,656).